Sunnyvale, CA, United States of America

Arrash Moghaddasi

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Roche Molecular Systems, Inc.. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Arrash Moghaddasi: Innovator in Genetic Engineering

Introduction

Arrash Moghaddasi is a notable inventor based in Sunnyvale, CA (US). He has made significant contributions to the field of genetic engineering, particularly in the development of bacteriophages and transduction particles. His innovative work has the potential to impact diagnostics and therapeutics for bacteria-related diseases.

Latest Patents

Moghaddasi holds a patent for "Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems." This invention relates to compositions and methods for producing genetically engineered bacteriophages and non-replicating transduction particles (NRTPs) that contain non-native tail fibers. These tail fibers display altered host specificity and reactivity, which can be utilized in developing novel diagnostics and therapeutics.

Career Highlights

Arrash Moghaddasi is currently associated with Roche Molecular Systems, Inc. His work at Roche focuses on advancing technologies that can lead to better solutions for bacterial infections. His innovative approach and dedication to research have positioned him as a key player in his field.

Collaborations

Moghaddasi collaborates with talented professionals, including Kalyani Mangipudi and Kyle C Cady. These collaborations enhance the research environment and contribute to the development of groundbreaking technologies.

Conclusion

Arrash Moghaddasi's contributions to genetic engineering and his innovative patent demonstrate his commitment to advancing medical science. His work has the potential to lead to significant advancements in the treatment of bacteria-related diseases.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…